{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:59:04Z","timestamp":1781139544002,"version":"3.54.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13390-8","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T11:14:53Z","timestamp":1777029293000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Infectious adverse events in patients treated with biotherapies in a tropical Amazonian context, French Guiana"],"prefix":"10.1186","volume":"26","author":[{"given":"Roxane","family":"Pasquer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dufens","family":"Pierre-Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houari","family":"Aissaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Louvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alolia","family":"Aboikoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanguy","family":"Gbaguidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Sidibe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malika","family":"Belgrine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mentine","family":"Montagnac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Deschamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Grotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Blaizot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"13390_CR1","doi-asserted-by":"publisher","unstructured":"Song X, Liang H, Nan F, Chen W, Li J, He L, et al. Autoimmune diseases: molecular pathogenesis and therapeutic targets. MedComm. 2025 juill;6(7):e70262. https:\/\/doi.org\/10.1002\/mco2.70262.","DOI":"10.1002\/mco2.70262"},{"issue":"4","key":"13390_CR2","first-page":"48","volume":"4","author":"P Singh","year":"2024","unstructured":"Singh P, Singh S. Immunotherapy in autoimmune diseases: a review of recent breakthroughs in using Immunotherapy for conditions like rheumatoid arthritis, lupus, and multiple sclerosis. IASR J Med Pharm Sci. 2024, Oct;4(4):48\u201354.","journal-title":"IASR J Med Pharm Sci"},{"key":"13390_CR3","doi-asserted-by":"publisher","first-page":"204062232312062","DOI":"10.1177\/20406223231206225","volume":"14","author":"HY Chiu","year":"2023","unstructured":"Chiu HY, Hung YT, Huang YH. Comparative short-term risks of infection and serious infection in patients receiving biologic and small-molecule therapies for psoriasis and psoriatic arthritis: a systemic review and network meta-analysis of randomized controlled trials. Ther Adv Chronic Disease. Janv. 2023;14:20406223231206225. https:\/\/doi.org\/10.1177\/20406223231206225.","journal-title":"Ther Adv Chronic Disease. Janv"},{"key":"13390_CR4","doi-asserted-by":"publisher","unstructured":"Idrissi Zaki F, Chekkouri FE, Mougui A, El Bouchti I. Complications infectieuses des bioth\u00e9rapies chez les patients atteints de rhumatisme inflammatoire chronique. Revue du Rhumatisme. d\u00e9c. 2022;89:A248. https:\/\/doi.org\/10.1016\/j.rhum.2022.10.389.","DOI":"10.1016\/j.rhum.2022.10.389"},{"issue":"5","key":"13390_CR5","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.eimce.2020.10.014","volume":"40","author":"I Nore\u00f1a","year":"2022","unstructured":"Nore\u00f1a I, Fern\u00e1ndez-Ruiz M, Aguado JM. Is there a real risk of bacterial infection in patients receiving targeted and biological therapies? Enferm Infecc Microbiol Clin (Engl ed.). 2022, mai;40(5):266\u201372. https:\/\/doi.org\/10.1016\/j.eimce.2020.10.014.","journal-title":"Enferm Infecc Microbiol Clin (Engl ed.)"},{"issue":"6","key":"13390_CR6","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.anai.2023.02.010","volume":"130","author":"L Cannon","year":"2023","unstructured":"Cannon L, Pan A, Kovalick L, Sarkissian A, Wu EY. Secondary immunodeficiencies and infectious considerations of biologic immunomodulatory therapies. Ann Allergy, Asthma Immunol. 2023;130(6):718\u201326. https:\/\/doi.org\/10.1016\/j.anai.2023.02.010.","journal-title":"Ann Allergy, Asthma Immunol"},{"issue":"3","key":"13390_CR7","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.revmed.2016.09.010","volume":"38","author":"M Catroux","year":"2017","unstructured":"Catroux M, Lauda-Maillen M, Pathe M, De Boisgrollier De Ruolz AC, Cazenave-Roblot F, Roblot P, et al. \u00c9v\u00e9nements infectieux survenus au cours des maladies auto-immunes trait\u00e9es par rituximab: \u00e0 partir d\u2019une \u00e9tude r\u00e9trospective de 93 cas. La Revue de M\u00e9decine Interne. 2017, mars;38(3):160\u201366. https:\/\/doi.org\/10.1016\/j.revmed.2016.09.010.","journal-title":"La Revue de M\u00e9decine Interne"},{"issue":"4","key":"13390_CR8","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/bjd\/ljac118","volume":"188","author":"K Kridin","year":"2023","unstructured":"Kridin K, Mruwat N, Amber KT, Ludwig RJ. Risk of infections in patients with pemphigus treated with rituximab vs. azathioprine or mycophenolate mofetil: a large-scale global cohort study. Br J Dermatol. Avr. 2023;188(4):499\u2013505. https:\/\/doi.org\/10.1093\/bjd\/ljac118.","journal-title":"Br J Dermatol. Avr"},{"issue":"3","key":"13390_CR9","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.revmed.2024.12.007","volume":"46","author":"L Piroth","year":"2025","unstructured":"Piroth L, Moretto F, Sixt T, Blot M. Complications virales des bioth\u00e9rapies\/th\u00e9rapies cibl\u00e9es anti-inflammatoires. La Revue de M\u00e9decine Interne. 2025, mars;46(3):146\u201354. https:\/\/doi.org\/10.1016\/j.revmed.2024.12.007.","journal-title":"La Revue de M\u00e9decine Interne"},{"issue":"10","key":"13390_CR10","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1080\/14787210.2018.1521270","volume":"16","author":"I Nore\u00f1a","year":"2018","unstructured":"Nore\u00f1a I, Fern\u00e1ndez-Ruiz M, Aguado JM. Viral infections in the biologic therapy era. Expert Rev Anti Infect Ther. 2018, oct, 3;16(10):781\u201391. https:\/\/doi.org\/10.1080\/14787210.2018.1521270.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"13390_CR11","doi-asserted-by":"publisher","first-page":"1247310","DOI":"10.3389\/fpubh.2023.1247310","volume":"11","author":"M Nacher","year":"2024","unstructured":"Nacher M, Basurko C, Douine M, Lambert Y, Rousseau C, Michaud C, et al. Contrasted life trajectories: reconstituting the main population exposomes in French Guiana. Front Public Health. 2024, janv, 11;11:1247310. https:\/\/doi.org\/10.3389\/fpubh.2023.1247310.","journal-title":"Front Public Health"},{"key":"13390_CR12","doi-asserted-by":"publisher","first-page":"102677","DOI":"10.1016\/j.tmaid.2023.102677","volume":"57","author":"M Nacher","year":"2024","unstructured":"Nacher M, Epelboin L, Bonifay T, Djossou F, Blaizot R, Couppi\u00e9 P, et al. Migration in French Guiana: implications in health and infectious diseases. Travel Med Infect Disease. Janv. 2024;57:102677. https:\/\/doi.org\/10.1016\/j.tmaid.2023.102677.","journal-title":"Travel Med Infect Disease. Janv"},{"key":"13390_CR13","doi-asserted-by":"publisher","first-page":"104916","DOI":"10.1016\/j.meegid.2021.104916","volume":"93","author":"B De Thoisy","year":"2021","unstructured":"De Thoisy B, Duron O, Epelboin L, Musset L, Qu\u00e9nel, Roche B, et al. Ecology, evolution, and epidemiology of zoonotic and vector-borne infectious diseases in French Guiana: transdisciplinarity does matter to tackle new emerging threats. Infect, Genet Evol. 2021, sept;93:104916. https:\/\/doi.org\/10.1016\/j.meegid.2021.104916.","journal-title":"Infect, Genet Evol"},{"key":"13390_CR14","doi-asserted-by":"publisher","unstructured":"Douine M, Bonifay T, Lambert Y, Mutricy L, Galindo MS, Godin A, et al. Zoonoses and gold mining: a cross-sectional study to assess yellow fever immunization, Q fever, leptospirosis and leishmaniasis among the population working on illegal mining camps in French Guiana. Neela VK, \u00c9diteur. PLoS Negl Trop Dis. 2022, ao\u00fbt, 15;16(8):e0010326. https:\/\/doi.org\/10.1371\/journal.pntd.0010326.","DOI":"10.1371\/journal.pntd.0010326"},{"key":"13390_CR15","doi-asserted-by":"publisher","unstructured":"Petiot A, Drak Alsibai K, Dossou C, Couppie P, Blaizot R. Leprosy in French Guiana, 2015 to 2021: dynamics of a Persistent Public health Problem. Acta Derm Venereol. 2023, mai, 5;103:adv 6246. https:\/\/doi.org\/10.2340\/actadv.v103.6246.","DOI":"10.2340\/actadv.v103.6246"},{"issue":"11","key":"13390_CR16","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1111\/ijd.14625","volume":"58","author":"R Loiseau","year":"2019","unstructured":"Loiseau R, Nabet C, Simon S, Ginouves M, Brousse P, Blanchet D, et al. American cutaneous leishmaniasis in French Guiana: an epidemiological update and study of environmental risk factors. Int J Dermatol. 2019, nov;58(11):1323\u201328. https:\/\/doi.org\/10.1111\/ijd.14625.","journal-title":"Int J Dermatol"},{"key":"13390_CR17","doi-asserted-by":"publisher","unstructured":"Blaizot R, Simon S, Ginouves M, Pr\u00e9vot G, Blanchet D, Ravel C, et al. Validation of swab sampling and SYBR Green-based real-time PCR for the diagnosis of cutaneous leishmaniasis in French Guiana. Pritt BS, \u00e9diteur. J Clin Microbiol. 2021, janv, 21;59(2):e02218\u201320. https:\/\/doi.org\/10.1128\/JCM.02218-20.","DOI":"10.1128\/JCM.02218-20"},{"key":"13390_CR18","doi-asserted-by":"crossref","unstructured":"Saidi N, Blaizot R, Pr\u00e9vot G, Aoun K, Demar M, Cazenave PA, et al. Clinical and immunological spectra of human cutaneous leishmaniasis in north Africa and French Guiana. Front. Immunol [Internet]. 2023 [cit\u00e9 20 juill 2025];14. Disponible sur: juill, 27;14. https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1134020\/full.","DOI":"10.3389\/fimmu.2023.1134020"},{"key":"13390_CR19","doi-asserted-by":"crossref","unstructured":"Couppi\u00e9 P, Blaizot R, Velvin CJ, Douine M, Combe M, Nacher M, et al. Mycobacterium ulcerans infection in French Guiana; Current state of knowledge. In: Pluschke, G, R\u00f6ltgen, K. Buruli, Ulcer, [Internet]. Cham: Springer International Publishing; 2019 [cit\u00e9 25 d\u00e9c 2025]. p. \u00e9diteurs. p. 77\u201385. Disponible sur: http:\/\/link.springer.com\/10.1007\/978-3-030-11114-4_4.","DOI":"10.1007\/978-3-030-11114-4_4"},{"key":"13390_CR20","doi-asserted-by":"publisher","unstructured":"Douine M, Gozlan R, Nacher M, Dufour J, Reynaud Y, Elguero E, et al. Mycobacterium ulcerans infection (Buruli ulcer) in French Guiana, South America, 1969\u20132013: an epidemiological study. LancetThe Lancet Planet Health. mai 2017;1(2):e65\u201373. https:\/\/doi.org\/10.1016\/S2542-5196(17)30009-8.","DOI":"10.1016\/S2542-5196(17)30009-8"},{"key":"13390_CR21","doi-asserted-by":"publisher","unstructured":"Kazanji M, Gessain A. Human T-cell lymphotropic virus types I and II (HTLV-I\/II) in French Guiana: clinical and molecular epidemiology. Cad. Sa\u00fade P\u00fablica. 2003, oct;19(5):1227\u201340. https:\/\/doi.org\/10.1590\/S0102-311X2003000500002.","DOI":"10.1590\/S0102-311X2003000500002"},{"issue":"10","key":"13390_CR22","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.3390\/jof9101005","volume":"9","author":"G Grotta","year":"2023","unstructured":"Grotta G, Couppie P, Demar M, Drak Alsibai K, Blaizot R. Fungal density in Lobomycosis in French Guiana: a proposal for a New clinico-histological and therapeutic classification. JoF. 2023, oct, 12;9(10):1005. https:\/\/doi.org\/10.3390\/jof9101005.","journal-title":"JoF"},{"issue":"3","key":"13390_CR23","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3390\/jof10030168","volume":"10","author":"J Valentin","year":"2024","unstructured":"Valentin J, Grotta G, Muller T, Bourgeois P, Drak Alsibai K, Demar M, et al. Chromoblastomycosis in French Guiana: epidemiology and practices, 1955\u20132023. JoF. 2024, f\u00e9vr, 22;10(3):168. https:\/\/doi.org\/10.3390\/jof10030168.","journal-title":"JoF"},{"issue":"2","key":"13390_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.respe.2019.09.012","volume":"68","author":"M Nacher","year":"2020","unstructured":"Nacher M, Deungoue S, Brousse P, Adenis A, Couppi\u00e9 P, Sobesky M. Calcul de l\u2019IP-DMS en Guyane: prendre en compte le poids r\u00e9el de la pr\u00e9carit\u00e9 et de l\u2019isolement. Revue d\u2019\u00c9pid\u00e9miologie et de Sant\u00e9 Publique. 2020;68(2):125\u201332. https:\/\/doi.org\/10.1016\/j.respe.2019.09.012.","journal-title":"Revue d\u2019\u00c9pid\u00e9miologie et de Sant\u00e9 Publique"},{"key":"13390_CR25","unstructured":"National Cancer Institute (NCI), U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 5.0, published 2017 November 27."},{"issue":"9","key":"13390_CR26","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1001\/jamadermatol.2021.2599","volume":"157","author":"L Penso","year":"2021","unstructured":"Penso L, Dray-Spira R, Weill A, Pina Vegas L, Zureik M, Sbidian E. Association between biologics use and risk of serious infection in patients with psoriasis. JAMA Dermatol. 2021, sept, 1;157(9):1056\u201365. https:\/\/doi.org\/10.1001\/jamadermatol.2021.2599.","journal-title":"JAMA Dermatol"},{"issue":"sup1","key":"13390_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/14740338.2016.1240783","volume":"15","author":"S Minozzi","year":"2016","unstructured":"Minozzi S, Bonovas S, Lytras T, Pecoraro V, Gonz\u00e1lez-Lorenzo M, Bastiampillai AJ, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016, d\u00e9c, 5;15(sup1):11\u201334. https:\/\/doi.org\/10.1080\/14740338.2016.1240783.","journal-title":"Expert Opin Drug Saf"},{"key":"13390_CR28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jare.2018.09.003","volume":"15","author":"L Quartuccio","year":"2019","unstructured":"Quartuccio L, Zabotti A, Del Zotto S, Zanier L, De Vita S, Valent F. Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: usefulness of administrative data. J Educ Chang Adv Res. Janv. 2019;15:87\u201393. https:\/\/doi.org\/10.1016\/j.jare.2018.09.003.","journal-title":"J Educ Chang Adv Res. Janv"},{"key":"13390_CR29","doi-asserted-by":"publisher","unstructured":"Yuan K, Chen Y, Zhong M, Lin Y, Liu L. Risk and predictive factors for severe dengue infection: a systematic review and meta-analysis. Wang MS, \u00e9diteur. PLoS One. 2022, avr, 15;17(4):e0267186. https:\/\/doi.org\/10.1371\/journal.pone.0267186.","DOI":"10.1371\/journal.pone.0267186"},{"issue":"5","key":"13390_CR30","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/ajd.14315","volume":"65","author":"L Adams","year":"2024","unstructured":"Adams L, Metin C, Stevenson A. Experience of dermatologic biologic therapy use and associated opportunistic infection management in Australia\u2019s Tropical North. Aust J Dermatol. ao\u00fbt. 2024;65(5):462\u201366. https:\/\/doi.org\/10.1111\/ajd.14315.","journal-title":"Aust J Dermatol. ao\u00fbt"},{"key":"13390_CR31","doi-asserted-by":"crossref","unstructured":"Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell LJ, MacDonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011 Feb 16;2016(4):CD008794. doi:10.1002\/14651858.CD008794.pub2.","DOI":"10.1002\/14651858.CD008794"},{"issue":"6","key":"13390_CR32","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1183\/13993003.01245-2015","volume":"46","author":"H Getahun","year":"2015","unstructured":"Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. d\u00e9c. 2015;46(6):1563\u201376.","journal-title":"Eur Respir J. d\u00e9c"},{"issue":"21\u201322","key":"13390_CR33","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00508-022-02062-7","volume":"134","author":"E Rath","year":"2022","unstructured":"Rath E, Bonelli M, Duftner C, Gruber J, Mandl P, Moazedi-Furst F, et al. National consensus statement by the Austrian societies for rheumatology, pulmonology, infectiology, dermatology and gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic disease modifying antirheumatic drugs (DMARDs). Wien Klin Wochenschr. 2022, nov;134(21\u201322):751\u201365. https:\/\/doi.org\/10.1007\/s00508-022-02062-7.","journal-title":"Wien Klin Wochenschr"},{"key":"13390_CR34","doi-asserted-by":"publisher","unstructured":"Evangelatos G, Koulouri V, Iliopoulos A, Fragoulis GE. Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors. Ther Adv Musculoskeletal. Janv. 2020;12:1759720X20930116. https:\/\/doi.org\/10.1177\/1759720X20930116.","DOI":"10.1177\/1759720X20930116"},{"issue":"5","key":"13390_CR35","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.4269\/ajtmh.19-0616","volume":"102","author":"AL Cogen","year":"2020","unstructured":"Cogen AL, Lebas E, De Barros B, Harnisch JP, Faber WR, Lockwood DN, et al. Biologics in leprosy: a systematic review and case report. Am J Trop Med Hyg. 2020, mai, 6;102(5):1131\u201336. https:\/\/doi.org\/10.4269\/ajtmh.19-0616.","journal-title":"Am. J. Trop. Med. Hyg"},{"key":"13390_CR36","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.ijid.2020.09.1190","volume":"101","author":"D Mitra","year":"2020","unstructured":"Mitra D. A randomized controlled trial of prednisolone vs TNF-alfa inhibitor infliximab in the management of type 1 lepra reaction in leprosy patients. Int J Multiling Infect Dis. d\u00e9c. 2020;101:454. https:\/\/doi.org\/10.1016\/j.ijid.2020.09.1190.","journal-title":"Int J Multiling Infect Dis. d\u00e9c"},{"issue":"10","key":"13390_CR37","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1111\/ijd.15645","volume":"60","author":"J Valentin","year":"2021","unstructured":"Valentin J, Drak Alsibai K, Bertin C, Couppie P, Blaizot R. Infliximab in leprosy type 1 reaction: a case report. Int J Dermatol. 2021, oct;60(10):1285\u201387. https:\/\/doi.org\/10.1111\/ijd.15645.","journal-title":"Int J Dermatol"},{"key":"13390_CR38","doi-asserted-by":"publisher","unstructured":"Mitra D. A randomized controlled trial of anti-TNF \u03b1 bio-similar Adalimumab vs. Prednisolone in the management of leprosy patients with New type 1 lepra reaction. Open Forum Infect Dis. 2017;4(suppl_1):SS675\u2013S675. https:\/\/doi.org\/10.1093\/ofid\/ofx163.1805.","DOI":"10.1093\/ofid\/ofx163.1805"},{"key":"13390_CR39","doi-asserted-by":"crossref","unstructured":"Nacher M, Marshall E, Bani-Sadr F, Peugny S, Denis B, Ouedraogo E, et al. Disseminated histoplasmosis in persons living with HIV, France and overseas Territories,1992\u20132021. Emerg Infect Dis [Internet]. juill 2025 [cit\u00e9 31 juill 2025]; 2025;31(7). Disponible sur: https:\/\/wwwnc.cdc.gov\/eid\/article\/31\/7\/24-1931_article.","DOI":"10.3201\/eid3107.241931"},{"issue":"11","key":"13390_CR40","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1017\/ice.2015.188","volume":"36","author":"V Belvisi","year":"2015","unstructured":"Belvisi V, Orsi GB, Del Borgo C, Fabietti P, Ianari A, Albertoni F, et al. Large nosocomial outbreak associated with a Norwegian scabies index case undergoing TNF-\u03b1 inhibitor treatment: management and Control. Infect Control Hosp Epidemiol. 2015, nov;36(11):1358\u201360. https:\/\/doi.org\/10.1017\/ice.2015.188.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"13390_CR41","unstructured":"Taher Y. Severe scabies presentations in the context of targeted immune treatments. J Retailing Dermat. 2025;10(270)."},{"key":"13390_CR42","doi-asserted-by":"publisher","unstructured":"Bajwa DS, Jassal-Prior P, Reynolds NJ. BI25 crusted scabies in a patient with down syndrome on risankizumab: a complex interaction of biologics, neurological background and immunodeficiency in psoriasis management. Br J Dermatol. 2024, juin, 28;191(Supplement_1):i149\u2013149. https:\/\/doi.org\/10.1093\/bjd\/ljae090.313.","DOI":"10.1093\/bjd\/ljae090.313"},{"issue":"3","key":"13390_CR43","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/jdv.19688","volume":"38","author":"R Blaizot","year":"2024","unstructured":"Blaizot R, Armanville F, Michaud C, Boceno C, Dupart O, Pansart C, et al. Scabies in French Guiana: quantitative and qualitative factors associated with therapeutic failure. Acad Dermatol Venereol. 2024, mars;38(3):602\u201312. https:\/\/doi.org\/10.1111\/jdv.19688.","journal-title":"Acad Dermatol Venereol"},{"issue":"5","key":"13390_CR44","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/ijd.14848","volume":"59","author":"T Malmontet","year":"2020","unstructured":"Malmontet T, Guarmit B, Gaillet M, Michaud C, Garceran N, Chanlin R, et al. Spectrum of skin diseases in Amerindian villages of the Upper Oyapock, French Guiana. Int J Dermatol. mai 2020;59(5):599\u2013605. https:\/\/doi.org\/10.1111\/ijd.14848.","journal-title":"Int J Dermatol"},{"issue":"9","key":"13390_CR45","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1111\/ijd.16324","volume":"61","author":"J Valentin","year":"2022","unstructured":"Valentin J, Niemetzky F, Gaillet M, Michaud C, Carbunar A, Demar M, et al. Spectrum of skin diseases in Maroon villages of the Maroni area, French Guiana. Int J Dermatol. 2022, sept;61(9):1137\u201344. https:\/\/doi.org\/10.1111\/ijd.16324.","journal-title":"Int J Dermatol"},{"key":"13390_CR46","doi-asserted-by":"publisher","unstructured":"Winthrop KL. Serious infections with antirheumatic therapy: are biologicals worse? Ann Rheumatic Dis. 2006, nov;65(Suppl 3):iii54\u201357. https:\/\/doi.org\/10.1136\/ard.2006.058503.","DOI":"10.1136\/ard.2006.058503"},{"issue":"7","key":"13390_CR47","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1016\/j.transproceed.2021.07.038","volume":"53","author":"L Cachera","year":"2021","unstructured":"Cachera L, Adenis A, Dueymes JM, Rochemont D, Guarmit B, Roura R, et al. What is the part of tropical diseases among infectious complications in renal transplant recipients in the Amazon? A 12-year multicenter retrospective analysis in French Guiana. Transpl Proc. 2021, sept;53(7):2242\u201351. https:\/\/doi.org\/10.1016\/j.transproceed.2021.07.038.","journal-title":"Transpl Proc"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13390-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13390-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13390-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:06:51Z","timestamp":1781136411000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13390-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13390"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13390-8","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in line with the Helsinki declaration. This study was approved by the ethics\/research directorate of the French Guiana University Hospital and was published on Health Data Hub with the name BIORISK. Informed consent was collected for all patients. According to French legislation (Law n\u00b0 2012\u2013300, passed on 5\n                      th\n                      March 2012), no further legal clearance was needed. The BIORISK database contained only medical data corresponding to the clinical variables exposed in the study, and all data were anonymized. This study does not contain any identifying patient data and consent for publication is not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"RB has received fees for scientific expertise and reimbursements for transport and accommodation from Sanofi and Novartis, unrelated to the present study. The other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1110"}}